Edition:
United States

Medicines Co (MDCO.O)

MDCO.O on Nasdaq

49.32USD
28 Apr 2017
Change (% chg)

$0.74 (+1.52%)
Prev Close
$48.58
Open
$48.56
Day's High
$49.67
Day's Low
$48.51
Volume
1,049,677
Avg. Vol
1,699,473
52-wk High
$55.95
52-wk Low
$30.80

Latest Key Developments (Source: Significant Developments)

The Medicines Company Q1 loss per share $1.44
Wednesday, 26 Apr 2017 07:15am EDT 

April 26 (Reuters) - Medicines Co :The Medicines Company reports first-quarter 2017 financial results.Q1 loss per share $1.44 from continuing operations.Q1 revenue $24.2 million versus $50.3 million.Q1 revenue view $31.2 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-1.30 -- Thomson Reuters I/B/E/S.Q1 adjusted loss per share $1.05 from continuing operations.Medicines Co - at March 31, 2017, company had $436.7 million in cash and cash equivalents compared to $541.8 million at end of 2016.Medicines Co - at March 31, 2017, company had $436.7 million in cash and cash equivalents compared to $541.8 million at end of 2016.  Full Article

Medicines Co, Alnylam Pharma announce agreement with FDA on phase III clinical program for inclisiran
Wednesday, 26 Apr 2017 07:00am EDT 

April 26 (Reuters) - Medicines Co :The medicines company and alnylam pharmaceuticals announce agreement with fda on phase iii clinical program for inclisiran.Medicines co- nda submission anticipated at or around end of 2019.Medicines co- company has received final, end-of-phase ii meeting minutes from fda.  Full Article

Medicines Co reports Q4 loss per share $1.77 from continuing operations
Tuesday, 28 Feb 2017 07:00am EST 

Medicines Co : The Medicines Company reports fourth-quarter and full-year 2016 financial results . Q4 loss per share $1.77 from continuing operations . Q4 revenue $25.2 million versus I/B/E/S view $26.9 million . Q4 earnings per share view $-1.43 -- Thomson Reuters I/B/E/S .Q4 adjusted loss per share $1.19 from continuing operations.  Full Article

Medicines Co says FDA accepts NDA filing for intravenous antibiotic carbavance
Tuesday, 21 Feb 2017 07:15am EST 

Medicines Co : The Medicines Company announces FDA filing acceptance of new drug application for intravenous antibiotic carbavance(meropenem-vaborbactam) . Medicines Co - FDA does not currently plan to hold an advisory committee meeting to discuss application .Medicines co says tango 2 trial is ongoing and company expects results to be available before end of Q3 of 2017.  Full Article

The Medicines Co reports Q2 earnings per share of $2.51 from continuing operations
Wednesday, 27 Jul 2016 07:00am EDT 

The Medicines Company Reports Second : "completed divestiture of non-core cardiovascular assets" . Quarter 2016 business and financial results . Q2 earnings per share $2.51 from continuing operations . Q2 revenue $54.7 million versus $74.5 million . Q2 adjusted loss per share $0.62 from continuing operations . Q2 revenue view $41.9 million -- Thomson Reuters I/B/E/S .Q2 earnings per share view $-1.16 -- Thomson Reuters I/B/E/S.  Full Article

Medicines Co gives Federal circuit rules for Medicines Co in Angiomax litigation
Tuesday, 12 Jul 2016 07:02am EDT 

Medicines Co [MDCO.O] : Federal circuit rules for medicines company in angiomax patent litigation . Federal circuit said company's orange book patents covering Angiomax(reg) that expire in 2028 were not invalid under "on sale" bar .Federal circuit also remanded remainder of issues on appeal and cross-appeal to original federal circuit panel.  Full Article

The Medicines Company prices $350 million of convertible notes
Monday, 6 Jun 2016 10:13pm EDT 

Medicines Co : Prices $350 million of convertible notes . Says priced its private offering of $350 million in aggregate principal amount of its convertible senior notes due 2023 . Says notes will bear interest at a rate of 2.75% per year, payable semi-annually . Expects to use portion of net proceeds of offering to repurchase approximately $220 million of its 1.375% convertible notes due 2017 . Conversion rate for notes will initially be 20.4198 shares of common stock per $1,000 principal amount . Estimates that net proceeds from offering will be approximately $339.7 million .Expects to use approximately $29.5 million of net proceeds from offering to pay cost of capped call transactions.  Full Article

Medicines Co intends to offer $350 mln of convertible notes
Monday, 6 Jun 2016 06:57am EDT 

Medicines Co : The medicines company announces intention to offer $350 million of convertible notes . Proposes to offer $350 million aggregate principal amount of convertible senior notes due 2023 . Expects to use a portion of net proceeds of offering to repurchase approximately $220 million of its 1.375% convertible notes due 2017 .Expects to grant to initial purchasers an option to purchase up to an additional $52.5 million aggregate principal amount of notes.  Full Article

Medicines expects to incur about $18 mln-$22 mln of pre-tax charges
Friday, 13 May 2016 04:57pm EDT 

Medicines Co : Estimates it will incur approximately $18 million to $22 million of pre-tax charges primarily during q2 of 2016 - sec filing .Pre-Tax charges in connection with company's entrance into purchase and sale agreement to divest certain cardiovascular products.  Full Article

The Medicines Co to divest non-core cardiovascular assets
Monday, 9 May 2016 07:22am EDT 

The Medicines Company : Total consideration of up to $792 million . Deal will result in anticipated reduction in annual SG&A and related research and development expenses of between $65 million and $80 million . To sell Cleviprex(Clevidipine), Kengreal(Cangrelor) and company's rights to Argatroban for injection to Chiesi USA, Inc and its parent company, Chiesi Farmaceutici S.p.a .Core cardiovascular assets to Chiesi Farmaceutici S.p.a.  Full Article

More From Around the Web

BRIEF-The Medicines Company Q1 loss per share $1.44

* The Medicines Company reports first-quarter 2017 financial results